Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity

被引:55
作者
Mitani, H
Takimoto, M
Hughes, TE
Kimura, M
机构
[1] Novartis Pharma KK, Tsukuba Res Inst, Div Res, Tsukuba, Ibaraki 3002611, Japan
[2] Novartis Inst Biomed Res, Summit, NJ 07901 USA
关键词
dipeptidyl peptidase IV; Fischer; 344; rat; glucose tolerance; high-fat diet; diabetes;
D O I
10.1254/jjp.88.442
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was performed to determine the effects of a high-fat diet on glucose metabolism after an oral glucose challenge in high-fat diet-fed dipeptidyl peptidase IV (DPP-IV) positive (+) and deficient (-) Fischer 344 (F344) rats and the effects of novel DPP-IV inhibitor NVP-DPP728 (1-{2-[(5-cyanopyridin-2-yl)amino]ethylamino}acetyl-2-cyano-(S)-pyrrolidine monohydrochloride salt) on glucose tolerance in high-fat diet-fed F344 rats. In DPP-IV(+) rats, a high-fat diet load caused impaired glucose tolerance, such as increases of plasma insulin and blood glucose concentrations after oral glucose challenge, compared with a standard chow-fed group. In contrast, no marked change in glucose tolerance was induced by the high-fat diet in DPP-IV(-) rats. Blood glucose concentrations in DPP-IV(-) rats after glucose challenge were significantly lower than in DPP-IV(+) rats under high-fat diet load conditions. In standard chow and high-fat diet-fed DPP-IV(+) rats, NVP-DPP728 significantly suppressed glucose excursions after glucose challenge by inhibiting the plasma DPP-IV activity, associated with the stimulation of early insulin secretion, NVP-DPP728 did not affect glucose tolerance in DPP-IV(-) rats under both conditions. These results indicate that the amelioration of glucose tolerance by NVP-DPP728 in DPP-IV(+) rats was directly due to the inhibition of plasma DPP-IV activity, which might be via the subsequent increase in endogenous incretin action.
引用
收藏
页码:442 / 450
页数:9
相关论文
共 35 条
[1]  
Ahrén B, 1998, BIOESSAYS, V20, P642, DOI 10.1002/(SICI)1521-1878(199808)20:8<642::AID-BIES7>3.0.CO
[2]  
2-K
[3]   Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats [J].
Balkan, B ;
Kwasnik, L ;
Miserendino, R ;
Holst, JJ ;
Li, X .
DIABETOLOGIA, 1999, 42 (11) :1324-1331
[4]   Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig [J].
Deacon, CF ;
Hughes, TE ;
Holst, JJ .
DIABETES, 1998, 47 (05) :764-769
[5]   Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig [J].
Deacon, CF ;
Pridal, L ;
Klarskov, L ;
Olesen, M ;
Holst, JJ .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 1996, 271 (03) :E458-E464
[6]   Glucagon-like peptides [J].
Drucker, DJ .
DIABETES, 1998, 47 (02) :159-169
[7]  
ERICKSON RH, 1992, J BIOL CHEM, V267, P21623
[8]   ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS [J].
GUTNIAK, M ;
ORSKOV, C ;
HOLST, JJ ;
AHREN, B ;
EFENDIC, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) :1316-1322
[9]   SUBCUTANEOUS INJECTION OF THE INCRETIN HORMONE GLUCAGON-LIKE PEPTIDE-1 ABOLISHES POSTPRANDIAL GLYCEMIA IN NIDDM [J].
GUTNIAK, MK ;
LINDE, B ;
HOLST, JJ ;
EFENDIC, S .
DIABETES CARE, 1994, 17 (09) :1039-1044
[10]   Inhibition of the activity of dipeptidyl peptidase IV as a treatment for type 2 diabetes [J].
Holst, JJ ;
Deacon, CF .
DIABETES, 1998, 47 (11) :1663-1670